Evidence map›Paper›PMID 39950748›Full record

ArticleCancer medicine2025

Survival Analysis of 4 Different Age Groups of Pancreatic Ductal Adenocarcinoma After Radical Resection From Retrospective Multi-Center Analysis (YPB-003).

Hiroto Matsui, Tatsuya Ioka, Toru Kawaoka, Tsuyoshi Takahashi, Toshihiro Inokuchi, Eijiro Harada, Kazuhiko Sakamoto, Ryuichiro Suto, Yoshinari Maeda, Taku Nishimura and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hiroto MatsuiDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine Ube, Yamaguchi, Japan.ORCID https://orcid.org/0000-0003-3588-8751
Tatsuya IokaYamaguchi University Hospital Cancer Center Ube, Yamaguchi, Japan.
Toru KawaokaDepartment of Surgery, Tokuyama Central Hospital, Tokuyama, Japan.
Tsuyoshi TakahashiDepartment of Surgery, Saiseikai Yamaguchi General Hospital, Yamaguchi, Japan.
Toshihiro InokuchiDepartment of Surgery, Yamaguchi Rosai Hospital, Sanyo-Onoda, Japan.
Eijiro HaradaDepartment of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Kazuhiko SakamotoDepartment of Surgery, Kanmon Medical Center, Shimonoseki, Japan.
Ryuichiro SutoDepartment of Surgery, Yamaguchi Prefectural Grand Medical Center, Hofu, Japan.
Yoshinari MaedaDepartment of Surgery, Tsushimi Hospital, Hagi, Japan.
Taku NishimuraDepartment of Gastroenterological Surgery, JCHO Shimonoseki Medical Center, Shimonoseki, Japan.
Yoshitaro ShindoDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine Ube, Yamaguchi, Japan.
Yukio TokumitsuDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine Ube, Yamaguchi, Japan.
Masao NakajimaDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine Ube, Yamaguchi, Japan.
Yuta KimuraDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine Ube, Yamaguchi, Japan.
Taro TakamiDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan.ORCID https://orcid.org/0000-0002-6689-4989
Katsuyoshi ItoDepartment of Radiology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Hidekazu TanakaDepartment of Radiation Oncology, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Kimikazu HamanoDepartment of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Hiroaki NaganoDepartment of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine Ube, Yamaguchi, Japan.ORCID https://orcid.org/0000-0002-7074-3315
Yamaguchi Pancreatic/Biliary Disease Study Group (YPB)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study aimed to investigate the efficacy of radical resection and postoperative adjuvant chemotherapy on the survival benefit in patients with pancreatic ductal adenocarcinoma (PDAC), stratified by age, frailty, and other factors in actual clinical practice.

methodsWe retrospectively analyzed the clinicopathological and follow-up data of 414 patients with PDAC who underwent surgical resection at nine institutions under the Yamaguchi Pancreat/Biliary Disease Study Group, between January 1997 and December 2016. Recurrence-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Associations between survival and prognostic factors were evaluated by univariate and multivariate analyses.

resultsThere were 30.5% of patients with PDAC who were aged < 65 years, 37.9% aged 65-74 years, 17.6% aged 75-79 years, and 14.0% aged ≥ 80 years. Notably, RFS declined with increasing age (median RFS: 12.9, 10.2, 9.4, and 7.4 months, respectively), although the differences were not significant (p = 0.223). OS significantly decreased with age (median OS: 21.6, 21.2, 17.0, and 13.9 months, respectively; p = 0.005). In patients aged < 75 years, independent prognostic factors identified by univariate and multivariate analyses included lymph node metastasis (hazard ratio [HR], 1.598; p = 0.007), tumor size (HR, 1.489; p = 0.043), R status (HR, 1.536; p = 0.011), and serum albumin levels (HR, 1.526; p = 0.031). In patients aged ≥ 75 years, a high modified frailty index (HR, 2.446; p = 0.012) emerged as an independent prognostic factor, along with lymph node metastasis, CA19-9 level (HR, 1.897; p = 0.017), and R status (HR, 2.087; p = 0.007).

conclusionThe prognosis for older patients with PDAC was shorter than that of younger patients. Frailty may contribute to their poorer prognosis in older age.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAdultAgedAged, 80 and overAge FactorsChemotherapy, AdjuvantFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPancreatectomyPrognosisRetrospective StudiesSurvival Analysisadjuvant chemotherapyfrailtygeriatric oncologypancreatic ductal adenocarcinomaradial resection

Identifiers

PMID39950748
PMCPMC11826832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.